Fully owned captive or protected cell: what's the difference?

What is each structure, in plain terms?

A captive is an insurance company owned and controlled by its insureds, set up mainly to insure their own risks. A single owner's version is often called a pure or single-parent captive, and one source describes the conventional company as wholly owned by its parent and designed to achieve maximum control over a risk management programme.

A protected cell company is different. It is a single legal entity made of a core and a number of ring-fenced cells, designed to separate each cell's assets and liabilities from the others and from the core. Cells are often used in rent-a-captive and sponsored captive arrangements, where an outside party owns the structure and users pay a fee for access. The same idea goes by other names in different places, such as segregated portfolio company or segregated account company.

Who owns and controls what?

In a rented or sponsored set-up, the sponsor puts up the statutory capital and generally charges a fee for the use of it and for organising and running the captive, while the renter takes part without owning or managing the company. One practitioner article notes that directors sit at the level of the whole cell company, not in each cell, so a cell that wants to change its business, write a new line or pay a dividend needs those directors' approval.

The same article says such approvals are not normally unreasonably withheld but that there is potential for conflict. Another warns that where the cell structure is owned by a captive manager or sponsor, its interests can differ from the participants', for example on pricing, claims handling or investment, and suggests disclosure, independent directors and regular audits as mitigants. The same article's list of disadvantages adds that renters may have no control over governance, coverages and limits.

How are assets and liabilities separated, and what are the limits?

The core protection is statutory. In one legal description, creditors of a cell can reach only that cell's assets (or the company's own assets if they dealt with it directly), not other cells' assets. An industry article similarly says each cell's assets and liabilities are effectively ring-fenced from creditors of other cells, and that the articles normally bar the general assets from covering a shortfall in a cell.

There are limits. First, in the cell model a cell is usually not a separate legal entity, so it contracts through the company on its behalf. Second, the same law firm notes there is no absolute assurance that foreign jurisdictions will treat these structures the same way, particularly where they have no similar legislation. Third, a law-firm review of a well-known US court case involving connected funds says the problem there was intermingled money, weak internal controls and records, and directors treating separate portfolios as one entity. Fourth, one commentator calls the idea that there is no risk of cross-contamination a misconception: the firewall depends on domicile law and the quality of legal documents, and in some places it has not been fully tested in court.

Practical terms matter too. Operating agreements often include limited-recourse wording, and owners may require collateral up to the programme limit and a clause obliging the participant to make good any shortfall immediately. So the ring-fence protects you from other participants' creditors, but it does not remove your own obligations to the facility.

What are the trade-offs in cost, capital and flexibility?

On the cell side, sources cite no commitment of funds for capitalisation, reduced administrative costs compared with owned captives, and less restrictive exit provisions. One broker says cells ordinarily cost up to 30% less to operate and start than a conventional company, and often have a lower minimum capital requirement. Another source says cells can usually be formed faster than a single-parent captive, and that the owner provides the directors, so less management time is needed from participants.

On the other side, the same article's list of disadvantages includes uncertain tax deductibility of premiums, expenses that can be higher than some conventional alternatives, reduced cash flow, a requirement to pay the full annual premium with a letter of credit in many cases, and the risk of the capital provider backing out. Tax treatment of an individual cell may also be uncertain in some regions. Some people also see a cell as less independent or prestigious than a standalone captive. These are general points, not tax advice, and they differ by location.

A single-parent captive, by contrast, generally offers the highest level of control, customisation and profit retention for one company but may need significant capital, dedicated management resources and direct regulatory compliance.

Is there a middle option?

Yes. In an incorporated cell, each cell is a separately registered legal entity with its own memorandum and articles and its own board of directors. Because it is a separate entity, it can transact with other cells, may offer an extra layer of comfort where foreign courts may not know the cell concept, and needs its own capital. It is still usually hosted by the cell company owner, who may require a director on its board.

How do you move from a cell to your own captive?

Sources suggest it can be done, but the route depends on structure and local law. A separate legal entity makes it easier for an incorporated cell to convert to a standalone captive or be merged into another entity. For protected cells, one legal source lists transfer to another cell company, a spin-off as a separate body corporate or cell under another jurisdiction's law, independent incorporation, and merger among the ways cells can leave a structure.

Some places are legislating for it. One trade report describes a US state law, in effect from 1 October 2024, allowing protected cells of sponsored captives to convert into a new captive without affecting the cell's assets, rights, obligations and liabilities. Whether anything similar applies to you is a question for local advice. Before choosing, ask how exit works in the participation agreement, who holds the collateral, how reserves and run-off are handled and how long the process takes.

What should you ask before deciding?

One consultant stresses that the legal framework and the quality of documentation drive the outcome, and not every domicile treats cells the same way. Ask who owns the cell company, what conflicts they may have, what you control, what collateral and shortfall obligations apply, how your cell is separated in practice, and what the exit and conversion route looks like. Take advice specific to your own situation and location from independent legal, tax and actuarial advisers before committing.

Sources

• Captive.com, What Is a Protected or Segregated Cell Captive? (7 June 2024; read 2 November 2026)
• Howden, Types of captives (no date shown; read 2 November 2026)
• Bedell Cristin, Cell companies: the segregation of assets and liabilities (22 July 2011; read 2 November 2026)
• Captive International, Protected cells and series captives: why structures matter in today's market (4 September 2025; read 2 November 2026)
• Captive International, The use of SPCs (3 December 2020; read 2 November 2026)
• Captive Review, New Connecticut captive regulations signed into law (17 July 2024; read 2 November 2026)